A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis

A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis is a phase 2, interventional study registered as NCT05359393 by Fudan University, with a registry enrolment figure of 52 participants, started 2022-12-01 and due to reach its primary completion in 2027-09-01. Interventions recorded: a combination therapy including tislelizumab. Conditions listed: Advanced Rectal Cancer; Liver Metastasis; Pulmonary Metastasis; Microsatellite Stable Colorectal Carcinoma. Primary outcome: NED rate. Colorectal eligibility wording from the registry: "* Initial colonoscopy and pathology: adenocarcinoma;". Sites: China. No results are recorded here; the registry entry is the source.